IRCT20190911044744N3招募中3 期
Evaluating the effect of empagliflozin on blood pressure, cardiovascular events, mortality and renal parameters in patients undergoing coronary artery bypass surgery admitted to the A coronary care unit
Yazd University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •Patients undergoing coronary artery bypass surgery
- •Not being allergic to empagliflozin
排除标准
- •Patients who cannot get enough information with echocardiography
- •History of taking pioglitazone at least 8 weeks before entering the study
- •Glomerular filtration rate less than 30 mg per minute per 1.73 square meters of body surface based on the CKD-EPI formula
- •Pregnant or lactating women
研究者
相似试验
招募中
不适用
Evaluation of the effect of Empagliflozin on blood glucose, BMI, HbA1c and insulin dose in patients with type 1 diabetesType 1 diabetes mellitusIRCT20130610013612N12Tabriz University of Medical Sciences60
招募中
3 期
Investigating the effect of empagliflozin on blood sugar control, edema, electrolytes and hypertensioIRCT20130812014333N217Kermanshah University of Medical Sciences134
招募中
3 期
The effect of empagliflozin on improvement of hematopeosis in diabetic cardiovascular patientIRCT20190806044451N1Zanjan University of Medical Sciences90
招募中
不适用
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate LevelsHematocrit ChangeCardiovascular PreventionEmpagliflozinSGLT2-InhibitorsTissue OxygenationNCT06284850Aristotle University Of Thessaloniki40
已完成
1 期
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30